ublituximab

FDA Drug Profile — BRIUMVI

ublituximab is listed in the FDA National Drug Code directory with 3 NDC codes, marketed under brand name including BRIUMVI. Available dosage forms: injection, solution, concentrate, solution, liquid.

Drug details

Generic Name
ublituximab
Brand Names
BRIUMVI
Application Number
BLA761238
Sponsor
TG Therapeutics, Inc.
NDC Codes
3
Dosage Forms
INJECTION, SOLUTION, CONCENTRATE, SOLUTION, LIQUID
Routes
INTRAVENOUS
Active Ingredients
UBLITUXIMAB, UBLITUXIMAB-XIIY

Indications and Usage

1 INDICATIONS AND USAGE BRIUMVI is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. BRIUMVI is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults ( 1 , 14 ).

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.